NGM Biopharmaceuticals, Inc.
Dr. Daniel Chan, PhD, is currently a senior PKPD scientist at NGM Biopharmaceuticals Inc. He was involved in the development of Voxzogo (vosoritide) for the treatment of achondroplasia in children at BioMarin Pharmaceutical Inc., and did his postdoc at University of California San Francisco (UCSF). He has worked in other therapeutic areas including immuno-oncology, ophthalmology, inflammatory bowel disease and HIV. He has been a member of ASCPT since 2016.